BCC 2025 | Optimizing immunotherapy for triple-negative breast cancer
Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, emphasizes the need for biomarkers to personalize treatment for triple-negative breast cancer (TNBC), currently treated with pembrolizumab. There is an absence of conclusive data on effective biomarkers for selecting patients who benefit, and collaborative efforts are needed to generate biomarker data from trials to offer tailored treatment options. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the case for triple negative breast cancer? So triple negative breast cancer is currently in the early setting as well as metastatic disease. Patients receive immunotherapy, pembrolizumab. There are no good data presented showing that there is an effective biomarker in selecting patients that really benefit, or the other way around, patients that don’t benefit at all...
What is the case for triple negative breast cancer? So triple negative breast cancer is currently in the early setting as well as metastatic disease. Patients receive immunotherapy, pembrolizumab. There are no good data presented showing that there is an effective biomarker in selecting patients that really benefit, or the other way around, patients that don’t benefit at all. But it’s really important to work together to get those biomarker data. And not from your own local trial, that’s nice to have, but I really think we need it from the phase three pivotal trials to offer patients a really tailored treatment and get rid of this one size fits all.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
